Severe Persistent Urinary Retention Following Treatment With Intravenous Lecanemab
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-10 · 45 (10) · 702-705
DOI: 10.1002/phar.70060 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 05.09.2025. Verfasst von Amber N Navarra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Urinary Retention. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: NIH National Instituties of Health.
Abstract (Originalsprache)
Lecanemab is an amyloid‐targeted antibody indicated for treating patients with amyloid‐confirmed early Alzheimer's Disease in mild dementia or mild cognitive impairment stages. We report here a case of a subject with early stage of Alzheimer's Disease dementia, amyloid positive, who developed severe acute urinary retention following his first dose of intravenous lecanemab. His urinary retention resolved after a week but recurred following the second intravenous dose 2 weeks later. Lecanemab was discontinued, but the urinary retention has persisted for 8 months indicating possible permanent adverse impact on the bladder. The Naranjo causality probability score was 6. The incidence of urinary retention with intravenous lecanemab is not known but given that elderly patients with dementia may have multiple risks for bladder dysfunction, clinicians should remain vigilant. It is hoped that newer formulations, such as subcutaneous lecanemab, may prove safer in such patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Neurology, Duke University School of Medicine, Durham, North Carolina, USA.
- Duke Memory Disorders Clinic, Duke University School of Medicine, Durham, North Carolina, USA.
- The Duke-UNC ADRC, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Amber N Navarra
Förderung
- NIH National Instituties of Health
Zitieren
APA
Navarra, A. N., Wang, L. A., Al-Sahlani, H., Liu, A. J., & Doraiswamy, P. M. (2025). Severe Persistent Urinary Retention Following Treatment With Intravenous Lecanemab. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(10), 702-705. https://doi.org/10.1002/phar.70060
Vancouver
Navarra AN, Wang LA, Al-Sahlani H, Liu AJ, Doraiswamy PM. Severe Persistent Urinary Retention Following Treatment With Intravenous Lecanemab. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(10):702-705. doi:10.1002/phar.70060
BibTeX
@article{Navarra2025,
author = {Navarra, Amber N and Wang, Laura A and Al-Sahlani, Heba and Liu, Andy J and Doraiswamy, P Murali},
title = {Severe Persistent Urinary Retention Following Treatment With Intravenous Lecanemab},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
volume = {45},
number = {10},
pages = {702--705},
doi = {10.1002/phar.70060}
}
EUVIMED